Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada.

BACKGROUND

In Canada, epidermal growth factor receptor (EGFR) inhibitor therapies in advanced non-small cell lung cancer (NSCLC) were initially approved regardless of

METHODS

This is a retrospective cohort study derived at ICES (formerly known as the Institute for Clinical and Evaluative Sciences) of advanced NSCLC patients diagnosed from 2007-2016 in Ontario, Canada, over the age of 65, who received at least one dose of first-line chemotherapy. The exposure of interest was receipt of second or later-line erlotinib. The primary outcome was the hazard ratio for mortality evaluated using a Cox proportional hazards model, and the secondary outcome, ED visits, was evaluated using a Poisson model.

RESULTS

First-line chemotherapy was administered in 30.4% of stage IV NSCLC patients. Of these patients, 19.7% received second or later-line erlotinib. The proportion of patients prescribed second or later-line erlotinib decreased over the course of the study (P<0.0001). Unadjusted median overall survival in the entire cohort was 325 days (95% CI: 314-337 days), 513 days (95% CI: 485-539 days) in the erlotinib cohort, and 282 days (95% CI: 270-291 days) in the non-erlotinib cohort. Despite this, the adjusted hazard ratio for death was 1.89 (95% CI: 1.73-2.07, P<0.0001) for patients on erlotinib. Patients receiving erlotinib also had a marginally higher relative rates of ED visits with an adjusted relative risk of 1.10 (95% CI: 1.02-1.19, P=0.013).

CONCLUSIONS

This study highlights the importance of using EGFR targeted treatments in NSCLC patients with a predictive biomarker, and suggests that treatment with erlotinib therapy is unlikely to benefit unselected patients with advanced NSCLC.

Informations de copyright

2021 Journal of Thoracic Disease. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/jtd-21-804). KP has received travel funding from Roche, continuing medical education speaker honorarium from Merck, Pfizer and Astra Zeneca, and consulting fees from Amgen. NBL has received continuing medical education speaker honoraria from Merck and Bristol Myers Squibb as well as institutional research funding from Array, Guardant Health, Pfizer, MSD, Roche, Astra Zeneca, Lilly, EMD Serono, Takeda, and Bayer. The other authors have no conflicts of interest to declare.